Related Experiment Video
Updated: May 17, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Pacific community's perceptions on how to improve uptake of urate-lowering therapy for Pacific gout patients
Samuela Ofanoa1, Malakai Ofanoa2, Siobhan Tu'akoi2
1Pacific Health Section, University of Auckland, 507, 28 Park Avenue, Grafton, Auckland, 1023, New Zealand. s.ofanoa@auckland.ac.nz.
Objectives:
This study aims to explore the views of Pacific people on how to improve the management of urate-lowering therapy among Pacific gout patients in South Auckland.
Methods:
The study used the Fa'afaletui model to explore the views on gout management across different perspectives of Pacific community members and health professionals working in health providers with high Pacific patient populations. Three workshops were delivered with the community and health professionals. All data were collected by note-takers and analysed using a general inductive approach. Participants were given the opportunity to review the results of the previous workshop before starting the next one.
Results:
The key findings from this study clustered into three key themes: [1] Gout interventions guided by Pacific frameworks and research; [2] a multifaceted approach including education, improved access to treatment and screening for gout, and strategies to help Pacific gout patients remain engaged and adherent; and [3] Pacific gout champions.
Conclusion:
This study presents the views of community members of how to improve the uptake of urate-lowering therapy among Pacific gout patients. The community highlighted the need for a multifaceted intervention governed by a Pacific model, addressing access barriers and education for Pacific gout patients.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Antihypertensive Drugs: Potassium-Sparing Diuretics
Phase II Reactions: Glucuronidation
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...

